Related Experiment Video
Updated: Jul 18, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and
Andreas Edsfeldt1, Isabel Gonçalves2, Isa Vigren3
1Department of Clinical Sciences Malmö, Lund University, Sweden; Department of Cardiology, Skåne University Hospital, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Sweden.
Insights
High levels of Interleukin-6 (IL-6) are linked to increased cardiovascular disease (CVD) risk and atherosclerosis. Soluble IL-6 receptor (sIL-6R) is not a reliable CVD risk marker but reflects plaque inflammation.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Medicine
Background:
- Residual cardiovascular disease (CVD) risk is linked to persistent vascular inflammation.
- Interleukin-6 (IL-6) is a key mediator of inflammation and a potential therapeutic target.
- IL-6 exerts its effects through direct receptor binding or via soluble IL-6 receptors (sIL-6R).
Purpose of the Study:
- To investigate the association between IL-6 and sIL-6R pathways and the risk of cardiovascular disease (CVD).
- To evaluate the relationship between IL-6/sIL-6R and atherosclerosis, arterial stiffness, and endothelial function.
- To determine the role of sIL-6R in plaque inflammation.
Main Methods:
- Analysis of IL-6 and sIL-6R in plasma samples from three large prospective cohorts (MDC, SUMMIT VIP, CPIP) using proximity extension assay.
- Longitudinal follow-up for incident cardiovascular events (myocardial infarction) and assessment of clinical outcomes.
- Immunohistochemistry and biochemical analysis of atherosclerotic plaques.
Main Results:
- Elevated plasma IL-6 levels were significantly associated with an increased risk of myocardial infarction (HR 2.60 [2.08-3.25]).
- High IL-6 correlated with increased atherosclerosis, arterial stiffness, and impaired endothelial function.
- Soluble IL-6 receptor (sIL-6R) showed no independent association with CVD risk or vascular function but was linked to plaque inflammation.
Conclusions:
- Plasma IL-6 is a significant risk marker for cardiovascular events and associated vascular pathologies.
- Soluble IL-6 receptor (sIL-6R) is not a reliable indicator of overall CVD risk.
- The association of sIL-6R with plaque inflammation suggests a complex role for IL-6 signaling in atherosclerosis.
Background:
The residual cardiovascular risk in subjects receiving guideline-recommended therapy is related to persistent vascular inflammation and IL-6 represents a target for its treatment. IL-6 binds to receptors on leukocytes and hepatocytes and/or by forming complexes with soluble IL-6 receptors (sIL-6R) binding to gp130 which is present on all cells. Here we aimed to estimate the associations of these two pathways with risk of cardiovascular disease (CVD).
Methods:
IL-6 and sIL-6R were analyzed using the proximity extension assay. Baseline plasma samples were obtained from participants in the prospective Malmö Diet and Cancer (MDC) study (n = 4661), the SUMMIT VIP study (n = 1438) and the Carotid Plaque Imaging Project (CPIP, n = 285). Incident clinical events were obtained through national registers. Plaques removed at surgery were analyzed by immunohistochemistry and biochemical methods.
Results:
During 23.1 ± 7.0 years follow-up, 575 subjects in the MDC cohort suffered a first myocardial infarction. Subjects in the highest tertile of IL-6 had an increased risk compared to the lowest tertile (HR and 95% CI 2.60 [2.08-3.25]). High plasma IL-6 was also associated with more atherosclerosis, increased arterial stiffness, and impaired endothelial function in SUMMIT VIP, but IL-6 was only weakly associated with plaque inflammation in CPIP. sIL-6R showed no independent association with risk of myocardial infarction, atherosclerosis severity or vascular function, but was associated with plaque inflammation.
Conclusions:
Our findings show that sIL-6R is a poor marker of CVD risk and associated vascular changes. However, the observation that sIL-6R reflects plaque inflammation highlights the complexity of the role of IL-6 in CVD.
Related Concept Videos
Inflammation
Atherosclerosis I: Introduction
The JAK-STAT Signaling Pathway
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease II: Pathophysiology
Intracellular Signaling Affects Focal Adhesions
Some...

